Cataplexy - Pipeline Insight, 2024

This “Cataplexy - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cataplexy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cataplexy Understanding

Cataplexy: Overview

Cataplexy is characterized by transient episodes of voluntary muscle weakness precipitated by intense emotion. The sudden onset of muscle weakness characterizes cataplexy. Such episodes are transient, lasting seconds to minutes, and get precipitated by intense emotions. Cataplectic attacks are more frequently incited by positive emotions (i.e., laughter, excitement, etc.) than negative emotions (i.e., anger, fear, frustration, etc.), with laughter being the most common precipitant. It is the complete or partial paralysis of voluntary muscles that is responsible for the weakness associated with cataplexy; however, it bears noting that the muscles of eye movement and respiration get spared during these attacks. The suppression of serotonergic and noradrenergic neuronal circuits permit the complete or partial paralysis of voluntary muscles.

Symptoms
The symptoms of Cataplexy include:

• Dropping eyelids
• Jaw dropping
• Head falling to the side due to neck muscle weakness
• Whole body falling to the ground
• Various muscles around your body twitching without an obvious cause

Diagnosis
Diagnosis of cataplexy is carried out by studying sleep (polysomnogram), which records the muscles and brain involved in sleeping. Multiple sleep latency test examines short naps throughout the day to study how quicky the patient’s falls asleep during the spacing of naps.

Treatment
The following pharmacologic agents are considered first-line in the management of cataplexy: Selective serotonin reuptake inhibitors (fluoxetine 10 to 80 mg by mouth daily every morning), norepinephrine reuptake inhibitors (atomoxetine 40 to 80 mg by mouth daily every morning), serotonin/norepinephrine reuptake inhibitors (venlafaxine extended-release 37.5 to 150 mg by mouth once daily every morning), and tricyclic antidepressants (clomipramine 10 to 150 mg by mouth daily every morning). Tricyclic antidepressants (TCAs) have fallen out of favor for the treatment of cataplexy due to their anticholinergic side effects (i.e., delirium, dry mucous membranes, hyperthermia, ileus, mydriasis, tachycardia, and urinary retention). Sodium oxybate, the sodium salt of gamma-hydroxybutyrate has recently got approval from FDA for the treatment of Cataplexy.

Cataplexy Emerging Drugs Chapters

This segment of the Cataplexy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cataplexy Emerging Drugs

FT218: Avadel FT218 is a drug which is a GABA B receptor agonists. Originally, this compound was owned by Flamel Technologies. FT218 is in Phase 3 of the clinical study and is presently under the development of Avadel. The trial initiated in June 2020 and is expected to complete by June 2022 with 250 enrolled participants.(NCT04451668)
AXS12: Axome Therapeutics
AXS12 (Reboxetine) is a Phase 2 drug in development for the treatment of cataplexy. It acts as adrenergic uptake inhibitor and is currently being developed by Axome Therapeutics.

Cataplexy: Therapeutic Assessment

This segment of the report provides insights about the different Cataplexy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cataplexy

There are approx. 3+ key companies which are developing the therapies for Cataplexy. The companies which have their Cataplexy drug candidates in the most advanced stage, i.e. phase III include, Avadel.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cataplexy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cataplexy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cataplexy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cataplexy drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cataplexy R&D. The therapies under development are focused on novel approaches to treat/improve Cataplexy.

Cataplexy Report Insights

• Cataplexy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cataplexy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cataplexy drugs?
• How many Cataplexy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cataplexy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cataplexy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cataplexy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Avadel
• Axome Therapeutics

Key Products

• FT218
• AXS12

This product will be delivered within 1-3 business days.